List of Paragraph IV Patent Certifications Feb-12, 2019
List of New Paragraph IV Certifications as of Aug 21, 2018
https://www.flickr.com/photos/baconizedhameister/
GlaxoSmithKline ($GSK) is preparing to move the granulocyte macrophage colony-stimulating factor (GMCSF) antibody it licensed from MorphoSys (ETR:MOR) into a Phase II trial in osteoarthritis of the hand. The move opens up a new possible indication for the drug, which GSK saw primarily as a treatment for rheumatoid arthritis when it picked it up in a €445 million ($483 million) deal.
Market Place
Share Share
Share Share
